104
Participants
Start Date
February 6, 2025
Primary Completion Date
August 31, 2027
Study Completion Date
August 31, 2027
Gemcitabine
1000 mg/m2, intravenously on day 1 and day 15, for subjects with basal-like cell type pancreatic carcinoma.
Nab paclitaxel
125 mg/m2 intravenously on day 1 and day 15 for subjects with basal-like cell type pancreatic carcinoma.
Erlotinib
50 mg per oral daily. for subjects with basal-like cell type pancreatic carcinoma.
NALIRIFOX
Subjects with classical pancreatic adenocarcinoma will receive. NALIRIFOX is liposomal irinotecan with 5-fluorouracil/leucovorin and oxaliplatin. Dosing and plan will be decided by the treating physician.
Folfirinox
Subjects with classical pancreatic adenocarcinoma will receive. Dosing and plan will be decided by the treating physician.
RECRUITING
University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center, Chapel Hill
UNC Lineberger Comprehensive Cancer Center
OTHER